Cytokinetics, Incorporated (CYTK) Position Raised by TIAA CREF Investment Management LLC
TIAA CREF Investment Management LLC increased its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 9.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 107,548 shares of the biopharmaceutical company’s stock after buying an additional 9,162 shares during the period. TIAA CREF Investment Management LLC owned approximately 0.26% of Cytokinetics, worth $1,382,000 as of its most recent filing with the SEC.
Several other large investors also recently added to or reduced their stakes in the stock. Alambic Investment Management L.P. boosted its stake in Cytokinetics, by 115.9% in the first quarter. Alambic Investment Management L.P. now owns 28,500 shares of the biopharmaceutical company’s stock worth $366,000 after buying an additional 15,300 shares during the period. Norges Bank acquired a new stake in Cytokinetics, during the fourth quarter worth $976,000. Piermont Capital Management Inc. acquired a new stake in Cytokinetics, during the first quarter worth $612,000. Capital Fund Management S.A. acquired a new stake in Cytokinetics, during the first quarter worth $213,000. Finally, Essex Investment Management Co. LLC acquired a new stake in Cytokinetics, during the first quarter worth $373,000. 56.50% of the stock is owned by institutional investors.
Cytokinetics, Incorporated (CYTK) traded up 2.263% on Monday, reaching $12.425. The company’s stock had a trading volume of 36,818 shares. The firm’s market cap is $666.80 million. Cytokinetics, Incorporated has a 12 month low of $8.51 and a 12 month high of $17.20. The firm has a 50 day moving average of $13.43 and a 200 day moving average of $13.03.
Cytokinetics, (NASDAQ:CYTK) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by $0.03. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $5.28 million. Analysts anticipate that Cytokinetics, Incorporated will post ($2.08) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Cytokinetics, Incorporated (CYTK) Position Raised by TIAA CREF Investment Management LLC” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/14/cytokinetics-incorporated-cytk-position-raised-by-tiaa-cref-investment-management-llc.html.
A number of equities research analysts recently weighed in on CYTK shares. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Cytokinetics, in a research note on Tuesday, April 25th. Zacks Investment Research cut Cytokinetics, from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 4th. Cowen and Company restated an “outperform” rating and issued a $19.00 price target (up previously from $17.00) on shares of Cytokinetics, in a research note on Saturday, April 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Cytokinetics, in a research note on Friday, May 19th. Finally, Morgan Stanley started coverage on Cytokinetics, in a research note on Monday, July 31st. They issued an “overweight” rating and a $24.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $21.30.
In other news, CEO Robert I. Blum sold 5,000 shares of the company’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $13.62, for a total transaction of $68,100.00. Following the transaction, the chief executive officer now owns 94,785 shares of the company’s stock, valued at approximately $1,290,971.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Caryn Gordon Mcdowell sold 11,348 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $12.47, for a total value of $141,509.56. Following the transaction, the insider now directly owns 21,570 shares in the company, valued at approximately $268,977.90. The disclosure for this sale can be found here. Insiders have sold a total of 26,348 shares of company stock worth $339,260 in the last ninety days. Insiders own 7.20% of the company’s stock.
Cytokinetics, Company Profile
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.